Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck astraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q2 2026
25
Period ended Jun 30, 2026
Change on a year earlier
-37.5%
40 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 25 | -37.5% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 24 | -25.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 30 | -31.8% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 31 | -20.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 40 | -7.0% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 32 | -17.9% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 44 | -10.2% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 39 | -11.4% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 43 | -15.7% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 39 | -17.0% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 49 | -2.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 44 | -2.2% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 51 | +10.9% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Mar 31, 2023 | 47 | +6.8% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 50 | -2.0% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2022 | Sep 30, 2022 | 45 | +2.3% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 46 | +7.0% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 44 | +10.0% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 51 | +6.3% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 44 | +10.0% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 43 | +10.3% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 40 | +21.2% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 48 | +14.3% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 40 | +11.1% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 39 | +18.2% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 33 | +22.2% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 42 | – | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 36 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 33 | – | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 27 | – | Form 10-Q (filed 2020-05-06) ↗ |
Cite this data
StockData. (2026). Merck AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_astrazeneca_sga
See every metric in the Merck KPI table. Data updated Oct 26, 2026.